Spatial biology company Nucleai has closed a $33 million Series B financing round led jointly by Section 32 and Sanofi Ventures, the firm announced on Tuesday.

Nucleai plans to use the new financing to advance its spatial analysis platform and expand its commercial footprint across biopharmaceutical companies and contract research organizations.

The company’s platform helps predict patient response to various cancer therapies by analyzing large datasets of tissue images to model spatial characteristics of tumors and patient immune systems. The technology is used in drug development, clinical treatment decisions, and for both retrospective and prospective patient stratification analysis in clinical trials.